2023
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory.
Alvero A, Fox A, Madina B, Krady M, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky T, Rutherford T, Mor G. Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory. Cancer Immunology Research 2023, 12: 261-274. PMID: 38078853, PMCID: PMC11027955, DOI: 10.1158/2326-6066.cir-23-0127.Peer-Reviewed Original ResearchPD-L1Immunological memoryImmune surveillanceLong-term anti-tumor effectsAnti-tumor immunological memoryAnti-tumor immune responseImmune modulatory capacityAnti-tumor responseOvarian cancer patientsAnti-tumoral responseAnti-tumor effectsImmune regulatory genesSelf-amplifying RNAVirus-like vesiclesPotent CD8MDSC expansionAdaptive armsCurrent immunotherapiesOncolytic capacityPrevent recurrenceAntitumor cytokinesCancer patientsImmune modulationImmune modulatorsOncolytic effect
2014
Renalase
Guo X, Wang L, Velazquez H, Safirstein R, Desir GV. Renalase. Current Opinion In Nephrology & Hypertension 2014, 23: 513-518. PMID: 24992568, PMCID: PMC4383282, DOI: 10.1097/mnh.0000000000000044.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsEnzymatic functionType 1 diabetesMitogen-activated protein kinase pathwayNucleotide polymorphismsProtein kinase BProtein kinase pathwayCellular actionsPlasma membraneKinase pathwayKinase BPotential therapeutic utilityCertain single nucleotide polymorphismsEnzymatic propertiesIschemic strokeImmune modulatorsRenalase geneTherapeutic utilityCytoprotective effectsClinical implicationsRenalaseConsistent associationPotential roleDiabetesCytokines
2013
The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus
Look M, Saltzman WM, Craft J, Fahmy TM. The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials 2013, 35: 1089-1095. PMID: 24183697, PMCID: PMC4164020, DOI: 10.1016/j.biomaterials.2013.10.046.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCells, CulturedDendritic CellsDrug CarriersFemaleImmunosuppression TherapyImmunosuppressive AgentsLactic AcidLupus Erythematosus, SystemicMiceMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NZBMycophenolic AcidNanogelsPermeabilityPolyethylene GlycolsPolyethyleneiminePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerConceptsDendritic cellsTherapeutic immunosuppressionLupus-prone NZB/W F1 miceNZB/W F1 miceW F1 miceCell immunosuppressionImmunosuppressive therapyInflammatory cytokinesImmune modulatorsF1 miceImmune responseImmunosuppressionVivo efficacySurface markersMycophenolic acidGreater reductionParticulate uptakeAttractive modalityEfficacyCellsNanoparticulate platformSuccessful deliveryImmunosuppressantsLupusCytokines
2010
Melanoma: A model for testing new agents in combination therapies
Ascierto PA, Streicher HZ, Sznol M. Melanoma: A model for testing new agents in combination therapies. Journal Of Translational Medicine 2010, 8: 38. PMID: 20406483, PMCID: PMC2873374, DOI: 10.1186/1479-5876-8-38.Peer-Reviewed Original ResearchConceptsC-Kit inhibitorsAdvanced melanomaImmune modulatorsIntroduction of interferonNew single agentsMulti-modality treatmentReliable predictive biomarkersSelection of patientsAdoptive cellular therapyAnti-angiogenesis agentsValidation of PatientAdditional molecular targetsImmunologic modulatorsAdvanced diseaseCombination therapyPredictive biomarkersIL-2High success rateIndividual patientsNew agentsSmall molecule inhibitorsPatientsSingle agentResponse rateAnticancer modalities
2008
Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer
Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer. Journal Of Immunotherapy 2008, 31: 569-576. PMID: 18528297, DOI: 10.1097/cji.0b013e318177a4ba.Peer-Reviewed Original ResearchConceptsIL-2 regimenMetastatic melanomaNormal saline fluid bolusesMetastatic renal cell cancerNew immune modulatorsTreatment-related deathsObjective response ratePercent of patientsRetrospective chart reviewSubset of patientsIL-2 dosesIntensive care unitRenal cell cancerRenal cancer patientsSubstantial acute toxicityDevelopment of combinationsChart reviewCare unitCell cancerMelanoma patientsOncology wardFluid bolusCancer patientsImmune modulatorsMedian number
2000
Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein
Sadeghi M, Collinge M, Pardi R, Bender J. Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein. The Journal Of Immunology 2000, 165: 2712-2718. PMID: 10946302, DOI: 10.4049/jimmunol.165.5.2712.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBiological TransportCell Adhesion MoleculesCells, CulturedCholesterolCytokinesDrug SynergismE-SelectinEndothelium, VascularGene Expression RegulationGTP-Binding Protein alpha Subunits, Gi-GoHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntercellular Adhesion Molecule-1Interleukin-1NF-kappa BRNA, MessengerSignal TransductionSimvastatinSodium FluorideUmbilical VeinsVascular Cell Adhesion Molecule-1ConceptsEffect of simvastatinCytokine-induced expressionIL-1Endothelial CAMsEndothelial cell adhesion molecules E-selectinNF-kappaBProinflammatory cytokines IL-1Cell adhesion molecules E-selectinAdhesion molecules E-selectinPotent immune modulatorG protein activator NaFCytokines IL-1G protein-coupled pathwayInhibitory G proteinCytokine-mediated activationSelectin mRNA levelsBasal toneProinflammatory cytokinesGialpha proteinsImmune modulatorsTNF-alphaICAM-1Pertussis toxinE-selectinEndothelial response
1997
Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras
Sultan P, Schechner J, McNiff J, Hochman P, Hughes C, Lorber M, Askenase P, Pober J. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nature Biotechnology 1997, 15: 759-762. PMID: 9255790, DOI: 10.1038/nbt0897-759.Peer-Reviewed Original ResearchConceptsSkin graftsLFA-3Human T-cell infiltrationIsotype-matched control antibodyT cell infiltrationSkin graft rejectionHuman skin graftsHuman skin allograftsCD2-LFA-3 interactionHuman LFA-3Microvascular injuryGraft rejectionLeukocyte infiltrationSkin allograftsImmune modulatorsControl antibodyInjury modelImmunodeficient miceImmune reactionsMouse/human chimeraMurine mAbsCD2 interactionPrincipal ligandGraftInjury
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply